XML 22 R13.htm IDEA: XBRL DOCUMENT v3.24.3
Investments in Other Entities
9 Months Ended
Sep. 30, 2024
Equity Method Investments and Joint Ventures [Abstract]  
Investments in Other Entities
5.
Investments in Other Entities

Equity Method

For the nine months ended September 30, 2024 and 2023, the Company’s equity method investment balance consisted of the following (in thousands):

 

% of
Ownership

 

December 31,
2023

 

 

Initial
Investment

 

 

Allocation
of Net
Income (Loss)

 

 

September 30, 2024

 

LaSalle Medical Associates – IPA line of business

 

25%

 

$

9,866

 

 

$

 

 

$

2,225

 

 

$

12,091

 

Pacific Medical Imaging & Oncology Center, Inc.

 

40%

 

 

1,691

 

 

 

 

 

 

(72

)

 

 

1,619

 

CAIPA MSO, LLC

 

30%

 

 

13,660

 

 

 

 

 

 

643

 

 

 

14,303

 

I Health, Inc.

 

25%

 

 

 

 

 

5,968

 

 

 

20

 

 

 

5,988

 

Other*

 

25%

 

 

557

 

 

 

 

 

 

71

 

 

 

628

 

 

 

 

$

25,774

 

 

$

5,968

 

 

$

2,887

 

 

$

34,629

 

 

 

% of
Ownership

 

December 31,
2022

 

 

Initial
Investment

 

 

Allocation
of Net
Income (Loss)

 

 

Funding

 

 

September 30, 2023

 

LaSalle Medical Associates – IPA line of business

 

25%

 

$

5,684

 

 

$

 

 

$

2,642

 

 

$

 

 

$

8,326

 

Pacific Medical Imaging & Oncology Center, Inc.

 

40%

 

 

1,878

 

 

 

 

 

 

(219

)

 

 

 

 

 

1,659

 

531 W. College, LLC **

 

50%

 

 

17,281

 

 

 

 

 

 

(387

)

 

 

700

 

 

 

17,594

 

One MSO, LLC **

 

50%

 

 

2,718

 

 

 

 

 

 

330

 

 

 

 

 

 

3,048

 

CAIPA MSO, LLC

 

30%

 

 

12,738

 

 

 

 

 

 

575

 

 

 

 

 

 

13,313

 

Other*

 

25%

 

 

 

 

 

325

 

 

 

163

 

 

 

 

 

 

488

 

 

 

 

$

40,299

 

 

$

325

 

 

$

3,104

 

 

$

700

 

 

$

44,428

 

*Other consists of smaller equity method investments.

** Investments were solely for the benefit of APC and its shareholders.

For three months ended September 30, 2024 and 2023, the Company’s equity method investment balance consisted of the following (in thousands):

 

% of
Ownership

 

June 30,
2024

 

 

Initial
Investment

 

 

Allocation
of Net
Income (Loss)

 

 

September 30, 2024

 

LaSalle Medical Associates – IPA line of business

 

25%

 

$

11,027

 

 

$

 

 

$

1,064

 

 

$

12,091

 

Pacific Medical Imaging & Oncology Center, Inc.

 

40%

 

 

1,648

 

 

 

 

 

 

(29

)

 

 

1,619

 

CAIPA MSO, LLC

 

30%

 

 

14,100

 

 

 

 

 

 

203

 

 

 

14,303

 

I Health, Inc.

 

25%

 

 

5,923

 

 

 

 

 

 

65

 

 

 

5,988

 

Other*

 

25%

 

 

578

 

 

 

 

 

 

50

 

 

 

628

 

 

 

 

$

33,276

 

 

$

 

 

$

1,353

 

 

$

34,629

 

 

 

% of
Ownership

 

June 30,
2023

 

 

Initial
Investment

 

 

Allocation
of Net
Income (Loss)

 

 

Funding

 

 

September 30, 2023

 

LaSalle Medical Associates – IPA line of business

 

25%

 

$

10,537

 

 

$

 

 

$

(2,211

)

 

$

 

 

$

8,326

 

Pacific Medical Imaging & Oncology Center, Inc.

 

40%

 

 

1,655

 

 

 

 

 

 

4

 

 

 

 

 

 

1,659

 

531 W. College, LLC **

 

50%

 

 

17,070

 

 

 

 

 

 

(176

)

 

 

700

 

 

 

17,594

 

One MSO, LLC **

 

50%

 

 

2,960

 

 

 

 

 

 

88

 

 

 

 

 

 

3,048

 

CAIPA MSO, LLC

 

30%

 

 

13,190

 

 

 

 

 

 

123

 

 

 

 

 

 

13,313

 

Other*

 

25%

 

 

420

 

 

 

 

 

 

68

 

 

 

 

 

 

488

 

 

 

 

$

45,832

 

 

$

 

 

$

(2,104

)

 

$

700

 

 

$

44,428

 

* Other consists of smaller equity method investments.

** Investments were solely for the benefit of APC and its shareholders.

 

I Health, Inc.

On March 31, 2024, a wholly owned subsidiary of the Company acquired a 25% equity interest in I Health, Inc. (“I Health”), a management service organization. The Company accounts for its investment in I Health under the equity method of accounting as the Company has the ability to exercise significant influence, but not control over, I Health’s operations. The purchase agreement includes a call option that allows the Company to purchase an additional 25% equity interest on each of the first, second, and third anniversary of the purchase (“I Health Call Option”). The total purchase price for this arrangement was $9.9 million, consisting of $3.9 million in the form of a call option, and $6.0 million as the initial investment of the 25% equity interest. Refer to Note 19 - “Fair Value Measurements of Financial Instruments” for additional information about the I Health Call Option.

There was no impairment loss recorded related to equity method investments for the three and nine months ended September 30, 2024 and 2023.